Similar mechanisms operate in hematological malignancies, where HMGB1 overexpression increases Bcl-2 levels and inhibits caspase-3/9 activation during adriamycin treatment, while HMGB1 knockdown restores chemosensitivity in resistant leukemia cells [118,119]. The gene discussed is HMGB1; the disease is leukemia.